 All treated children will have clinical and HIV genotype and subtype data blood sent to U. Wisconsin for analysis collected prior to starting ARVs. Children will then receive as initial therapy for HIV infection 2 NRTIs AZT, d4T, ABC or ddI and 1 NNRTI Neverapine, or Efavirenz or Kaletra a protease inhibitor. One month after starting ARVs and every four months thereafter during the study period an HIV viral load will be obtained. If the child is failing therapy, clinical data at the time of failure will be collected and blood will be drawn for repeat viral load, HIV-1 subtyping has the subtype changed, and genotypic analysis see below. Decisions on what to use as treatment for those children failing their first antiretroviral regimen will be made using the data collected on the blood obtained from each child in the study. 